TITLE
16 OCCUPATIONAL AND
PROFESSIONAL LICENSING
CHAPTER 2 ACUPUNCTURE
AND ORIENTAL MEDICINE PRACTITIONERS
PART 19 EXPANDED
PRACTICE CERTIFICATIONS
16.2.19.1 ISSUING AGENCY: New Mexico Board of Acupuncture and Oriental
Medicine.
[16.2.19.1 NMAC – Rp, 16.2.19.1
NMAC, 6-16-2015]
16.2.19.2 SCOPE:
All doctors of oriental medicine who are certified for expanded practice
or who are applicants for certification for expanded practice, as well as all educational
programs and students enrolled in an educational program.
[16.2.19.2 NMAC – Rp,
16.2.19.2 NMAC, 6-16-2015]
16.2.19.3 STATUTORY AUTHORITY: This part is promulgated pursuant to the
Acupuncture and Oriental Medicine Practice Act, Section 61-14A-8.1.
[16.2.19.3 NMAC – Rp,
16.2.19.3 NMAC, 6-16-2015]
16.2.19.4 DURATION: Permanent.
[16.2.19.4 NMAC – Rp,
16.2.19.4 NMAC, 6-16-2015]
16.2.19.5 EFFECTIVE DATE: June 16, 2015, unless a later date is cited at the end of
a section.
[16.2.19.5 NMAC – Rp,
16.2.19.5 NMAC, 6-16-2015]
16.2.19.6 OBJECTIVE:
This part lists the certification requirements for each of the following
expanded practice categories: basic injection therapy, injection therapy,
intravenous therapy and bioidentical hormone therapy.
[16.2.19.6 NMAC – Rp,
16.2.19.6 NMAC, 6-16-2015]
16.2.19.7 DEFINITIONS:
A. The
definitions in this section are in addition to those in the act and 16.2.1.7
NMAC.
B. The following
definition applies to the rules and the act: “educational course” is a comprehensive foundation of studies, approved by the
board leading to demonstration of entry level competence in the specified
knowledge and skills required for the four respective certifications in
expanded practice; an educational course is not an educational program as this
term is used in the act and the rules and as defined in 16.2.1 NMAC.
C. The following
definitions are from 16.19.36 NMAC for clarification of regulations for doctors
of oriental medicine, certified in expanded practice;
(1) “Air changes per hour” (ACPH) means
the number of times a volume of air equivalent to the room passes through the
room each hour.
(2) Ante-area” means an ISO Class 8 or better area where
personnel hand hygiene and garbing procedures, staging of components, order
entry, CSP labeling, and other high-particulate generating activities are
performed. It is also a transition area
that:
(a) provides assurance that pressure
relationships are constantly maintained so that air flows from clean to dirty
areas; and
(b) reduces the
need for the heating, ventilating, and air-conditioning (HVAC) control system
to respond to large disturbances.
(3) “Aseptic
Technique” means proper manipulation of preparations to maintain sterility
(4) "ASHP"
American Society of Health-Systems Pharmacists.
(5) Beyond-use date” (BUD) means the date, or as
appropriate, date and time, after which a compounded preparation is not to be
used and is determined from the date and time the preparation is compounded.
(6) “Biological safety cabinet” (BSC) means a ventilated
cabinet that provides ISO Class 5 environment for CSP’s, provides personnel,
preparation, and environmental protection having an open front with inward
airflow for personnel protection, downward high-efficiency particulate air
(HEPA)-filtered laminar airflow for preparation protection, and HEPA-filtered
exhausted air for environmental protection.
(7) “Buffer area” means an area
where the primary engineering control (PEC) is physically located. Activities that occur in this area include
the staging of components and supplies used when compounding CSP’s.
(8) “Certification” means independent third party
documentation declaring that the specific requirements have been met.
(9) Cleanroom” means a room in which the concentration of airborne particles is
controlled to meet a specified airborne particulate cleanliness class.
Microorganisms in the environment are monitored so that a microbial level for
air, surface, and personnel gear are not exceeded for a specified cleanliness
class.
(10) “Closed system
vial-transfer device” means a vial-transfer system that allows no
venting or exposure of substances to the environment.
(11) Compounded sterile preparations”(CSP’s) include, but are not limited, to the following
dosage forms which must be sterile when administered to patients:
(a) parenteral
preparations;
(b) aqueous
bronchial and nasal inhalations;
(c) injections
(e.g. colloidal dispersions, emulsions, solutions, suspensions);
(d) irrigations
for wounds and body cavities;
(e) ophthalmic
drops and ointments; and
(12) “Compounding aseptic isolator” (CAI)
means an enclosed ISO Class 5 environments for
compounding pharmaceutical ingredients or preparations. It is designed to
maintain an aseptic compounding environment within the isolator throughout the
compounding and material transfer processes. Air exchange into the
isolator from the surrounding environment should not occur unless the air has
first passed through a microbial retentive filter (HEPA minimum).
(13) “Critical area” means an ISO Class 5
environment.
(14) “Critical site” means a location that
includes any component or fluid pathway surfaces (e.g., vial septa, injection
ports, beakers) or openings (e.g., opened ampules, needle hubs) exposed and at
risk of direct contact with air (e.g., ambient room or HEPA filtered), moisture
(e.g., oral and mucosal secretions), or touch contamination. Risk
of microbial particulate contamination of the critical site increases with the
size of the openings and exposure time.
(15) “Direct compounding area” (DCA)
means a critical area within the ISO Class 5 primary engineering control
(PEC) where critical sites are exposed to unidirectional HEPA-filtered air,
also known as first air.
(16) “Disinfectant” means an agent that
frees from infection and destroys disease-causing pathogens or other harmful
microorganisms, but may not kill bacterial and fungal spores. It refers to substances applied to inanimate
agents, usually a chemical agent, but sometimes a physical one.
(17) “Home care” means
health care provided in the patient’s home (not a hospital or skilled nursing
facility) by either licensed health professionals or trained caregivers. May include hospice care.
(18) “Immediate use” means administration begins
not later than one (1) hour following the start of the compounding procedure. Use of Immediate use products is reserved to
those events in which delay in preparation would subject the patient to
additional risk due to delay in therapy and meeting USP/NF <797>
(Immediate-Use CSP Provision) criteria.
(19) “ISO 5” means air containing no more
than one hundred (100) particles per cubic foot of air of a size at least 0.5
micron or larger in diameter (3520 particles per cubic meter).
(20) “ISO 7” means air containing no more
than ten thousand (10,000) particles per cubic foot of air of a size at least
0.5 micron or larger in diameter (352,000 particles per cubic meter).
(21) “ISO 8” means air containing no more than one
hundred thousand (100,000) particles per cubic foot of air of a size at least
0.5 micron or larger in diameter (3,520,000 particles per cubic meter).
(22) “Laminar airflow” means a
non-turbulent, non-mixing streamline flow of air in parallel layers.
(23) “Laminar airflow workbench” (LAFW)
means a ventilated cabinet for compounding of sterile preparations. Provides
preparation protection with high-efficiency particulate air (HEPA) filtered
laminar airflow, ISO Class 5. Airflow may be horizontal (back to front) or
vertical (top to bottom) in direction.
(24) “Media-fill test” means a test used to
qualify aseptic technique of compounding personnel or processes and to ensure
that the processes used are able to produce sterile preparation without
microbial contamination. During this test, a microbiological growth medium such
as soybean-casein digest medium is substituted for the actual drug product to
simulate admixture compounding. The issues to consider in the development
of a media-fill test are media-fill procedures, media selection, fill volume,
incubation, time, and temperature, inspection of filled units, documentation,
interpretation of results, and possible corrective actions required.
(25) “Multiple-dose container” means
a multiple-unit container for articles or preparations intended for parenteral
administration only and usually containing antimicrobial preservatives. Once opened or entered, a multiple dose
container with antimicrobial preservative has a BUD of 28 days unless otherwise
specified by the manufacturer.
(26) “Negative pressure room”
means a room that is at a lower pressure than the adjacent spaces and
therefore, the net flow of air is into the room.
(27) “Parenteral product” means any
preparation administered by injection through one (1) or more layers of skin
tissue.
(28) “Personal protective equipment” (PPE) means
items such as gloves, gowns, respirators, goggles, face shields, and others
that protect individual workers from hazardous physical or chemical exposures.
(29) “Plan of care” means an individualized
care plan for each patient receiving parenteral products in a home setting to
include the following:
(a) description of actual or
potential drug therapy problems and their proposed solutions;
(b) a description of desired outcomes
of drug therapy provided;
(c) a proposal
for patient education and counseling; and
(d) a plan specifying proactive objective
and subjective monitoring (e.g. vital signs, laboratory test, physical
findings, patient response, toxicity, adverse reactions, and noncompliance) and
the frequency with which monitoring is to occur.
(30) “Positive pressure room” means a room
that is at a higher pressure than the adjacent spaces and, therefore, the net
airflow is out of
the room.
(31) “Preparation” means a CSP that is a
sterile drug or nutrient compounded in a licensed pharmacy or other
healthcare-related facility pursuant to the order of a licensed prescriber; the
article may or may not contain sterile products.
(32) “Product” means a commercially
manufactured drug or nutrient that has been evaluated for safety and efficacy
by the FDA. Products are accompanied by full prescribing information, which is
commonly known as the FDA-approved manufacturer’s labeling or product package
insert.
(33) “Quality assurance” means a program for
the systematic monitoring and evaluation of the various aspects of a service or
facility to ensure that standards of quality are being met.
(34) “Quality control” means a system for
verifying and maintaining a desired level of quality in a preparations or
process, as by planning, continued inspection, and corrective action as
required.
(35) “Single-dose container” means a
single-dose, or a single-unit, container for articles or preparations intended
for parenteral administration only. It is intended for a single use. Examples of single-dose containers include
prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed
containers when so labeled.
(36) “Secondary engineering control” means
the ante area and buffer area or cleanroom in which primary engineering
controls are placed.
(37) “Segregated compounding area” means a
designated space, either a demarcated area or room, that is restricted to
preparing low-risk level CSP’s with twelve (12)-hour or less BUD. Such area
shall contain a device that provides unidirectional airflow of ISO Class 5 air
quality for preparation of CSP’s and shall be void of activities and materials
that are extraneous to sterile compounding.
(38) “Standard operating procedure” (SOP) means a
written protocol detailing the required standards for performance of tasks and
operations within a facility.
(39) “Sterile” means free from bacteria or other
living microorganisms.
(40) “Sterilization by
filtration” means passage of a fluid or solution through a sterilizing
grade membrane to produce a sterile effluent.
(41) “Sterilizing grade membranes” means membranes
that are documented to retain one hundred percent (100%) of a culture of
107 microorganisms of a
strain of Brevundimonas (Pseudomonas) diminuta per square
centimeter of membrane surface under a pressure of not less than 30 psi. Such
filter membranes are nominally at 0.22 mm or 0.2 mm porosity, depending on
the manufacturer’s practice.
(42) “Unidirectional flow” means airflow moving in
a single direction in a robust and uniform manner and at sufficient speed to
reproducibly sweep particles away from the critical processing or testing area.
(43) “USP 797” United States Pharmacopeia Chapter
<797> Pharmaceutical Compounding.
(44) Sterile Preparations- This general
Chapter provides procedures and requirements for compounding sterile
preparations. General Chapter<797>
describes conditions and practices to prevent harm to patients that could
result from microbial contamination, excessive bacterial endotoxins,
variability in intended strength, unintended chemical and physical
contaminants, and ingredients of inappropriate quality in compounded sterile
preparations.
(45) “USP/NF standards” means United States
pharmacopeia/national formulary.
[16.2.19.7 NMAC – Rp,
16.2.19.7 NMAC, 6-16-2015]
16.2.19.8 EXPANDED PRACTICE CERTIFICATION
GENERAL PROVISIONS:
The four (4) categories of expanded
practice certification authorized by 61-14A-8.1. NMSA 1978 and defined in
16.2.19 NMAC that include, basic injection therapy, injection therapy,
intravenous therapy and bioidentical hormone therapy shall all include the
following provisions:
A. a doctor of
oriental medicine or enrolled in an educational course shall be authorized to
perform the techniques and shall have the prescriptive authority, for the
duration of the course, to administer and compound the substances that are
authorized in the expanded practice formulary for which he is studying under
the supervision of the board approved teacher for that educational course;
under other circumstances the student shall not be authorized to obtain,
prescribe or dispense such substances;
B. upon receipt of a current copy of CPR/BLS card the
board shall annually renew the expanded practice certifications of a doctor of
oriental medicine in good standing if the licensee has completed all continuing
education required by 16.2.9 NMAC;
C. all expanded
practice and prescriptive authority certifications shall automatically
terminate when licensure as a doctor of oriental medicine:
(1) is placed on inactive status as specified in 16.2.15 NMAC;
(2) expires as specified in 16.2.8 NMAC; or
(3) is suspended, revoked or terminated for any reason as
defined in 16.2.12 NMAC;
D. Proof of completion of
an ASHP course relative to USP 797 is required for the first time renewal of
basic injection therapy.
E. an expanded practice
certification that is revoked or terminated shall not be reinstated; the doctor
of oriental medicine must reapply for expanded practice certification as a new
applicant;
F. all expanded practice
certifications that were automatically terminated due to inactive status,
expiration or suspension as specified in Subsection E of 16.2.19.8 NMAC, shall
be automatically reinstated when licensure as a doctor of oriental medicine is
reinstated, provided that:
(1) all fees required by 16.2.10 NMAC have been paid;
(2) all continuing education requirements specified in 16.2.9
NMAC have been completed; and
(3) all other relevant, reinstatement provisions, required by
board rule, have been completed;
G. each year the board
may review the expanded practice formularies for necessary amendments; when new
substances are added to a formulary, appropriate education in the use of the
new substances shall be approved and required by the board and the board of
pharmacy for doctors of oriental medicine applying for new certification or as
continuing education for renewal of the applicable expanded practice
certification or certifications;
H. a doctor of oriental
medicine certified for a category of expanded practice under 16.2.19 NMAC that
authorizes the use of testosterone, a controlled substance, and any other drug
that is classified as a controlled substance, shall register with the federal
DEA (drug enforcement agency) prior to obtaining, prescribing, administering,
compounding or dispensing the controlled substance;
I. a doctor of
oriental medicine certified for expanded practice, when prescribing, shall use
prescription pads printed with his or her name, address, telephone number,
license number and his or her specific expanded practice certifications; if a
doctor of oriental medicine is using a prescription pad printed with the names
of more than one (1) doctor of oriental medicine, the above information for
each doctor of oriental medicine shall be on the pad and the pad shall have a
separate signature line for each doctor of oriental medicine; each specific
prescription shall indicate the name of the doctor of oriental medicine for
that prescription and shall be signed by the prescribing doctor of oriental
medicine;
J. a doctor of
oriental medicine certified for expanded practice shall always, when diagnosing
and treating a patient, use the skill and care ordinarily used by reasonably
well-qualified doctors of oriental medicine similarly certified and practicing
under similar circumstances, giving due consideration to the locality involved;
failure to comply with this fundamental requirement may result in denial,
suspension or revocation of licensure or certification, or other disciplinary
measures, pursuant to the provisions of the act, NMSA 1978, Section 61-14A-17,
and the Uniform Licensing Act, NMSA 1978, Section 61-1-1, et seq.;
K. when a doctor of
oriental medicine is certified for injection therapy, this certification
automatically supersedes his certification for basic injection therapy; and
L. the provisions for certification transition from extended prescriptive authority (Rx1) and expanded prescriptive authority (Rx2) to the expanded practice categories specified in 16.2.19 NMAC.
[16.2.19.8 NMAC – Rp,
16.2.19.8 NMAC, 6-16-2015]
16.2.19.9 EXPANDED PRACTICE CERTIFICATION
BOARD REQUIREMENTS:
A. The board shall
have final authority for certification of all applicants.
B. The board shall
notify the applicant in writing by mail postmarked no more than thirty (30)
days after the receipt of the initial application as to whether the application
is complete or incomplete and missing specified application documentation.
C. The board shall
notify the applicant in writing by mail postmarked no more than thirty (30)
days after the notice of receipt of the complete application sent out by the
board, whether the application is approved or denied.
D. If the
application is denied, the notice of denial shall state the reason the
application was denied.
E. In the interim
between regular board meetings the board’s chairman or an authorized designee
of the board shall approve an expanded practice certification to a qualified
applicant who has filed, with the board, a complete application and complied
with all requirements for expanded practice certification. The temporary expanded practice certification
will be ratified by the board on the date of the next regular board meeting. Final expanded practice certification shall
only be granted by the board.
F. the board shall
maintain a list of each doctor of oriental medicine who is certified for each
expanded practice category and shall notify the New Mexico board of pharmacy of
all such certified licensees;
G. The board shall
have the authority to deny, suspend, revoke or otherwise discipline an expanded
practice certification, in accordance with the Uniform Licensing Act, 61-1-1 to
61-1-31 NMSA 1978, for reasons authorized in the act and clarified in 16.2.12
NMAC.
[16.2.19.9 NMAC – Rp,
16.2.19.9 NMAC, 6-16-2015]
16.2.19.10 EXPANDED
PRACTICE SCOPE OF PRACTICE: (from 16.2.2.10 NMAC):
A. In addition to the scope of practice outlined in section 16.2.2 NMAC for a doctor of oriental medicine in New Mexico, the scope of practice for those certified in expanded practice shall include certification in any or all of the following modules: (61-14A-8.1BNMSA1978) basic injection therapy, injection therapy, intravenous therapy and bio-identical hormone therapy as specified in 16.2.19 NMAC.
B. The scope of practice for those doctors of oriental medicine certified in expanded practice shall also include the expanded practice and prescriptive authority defined in 61-14A-8.1C NMSA1978.
[16.2.19.10 NMAC – Rp,
16.2.19.10 NMAC, 6-16-2015]
16.2.19.11 BASIC INJECTION THERAPY
CERTIFICATION: The board shall issue, to a doctor of
oriental medicine, certification for basic injection therapy upon completion of
the course prerequisites including 30 hours of Pharmacology as specified in
16.2.18.9 and the following requirements.
A. The doctor of
oriental medicine shall be a doctor of oriental medicine in good standing.
B. The doctor of
oriental medicine shall submit to the board the completed application form
provided by the board.
C. The doctor of
oriental medicine shall pay the application fee for expanded practice
certification specified in 16.2.10 NMAC.
D. The doctor of
oriental medicine shall submit, with the application, proof of successful
completion of the basic injection therapy educational course specified in
16.2.18 NMAC.
[16.2.19.11 NMAC – Rp,
16.2.19.11 NMAC, 6-16-2015]
16.2.19.12 INJECTION
THERAPY CERTIFICATION: The board shall issue to a
doctor of oriental medicine, certification for injection therapy, upon
completion of the following requirements.
A. The doctor of
oriental medicine shall be a doctor of oriental medicine in good standing.
B. The doctor of
oriental medicine shall submit to the board the completed application form
provided by the board.
C. The doctor of
oriental medicine shall pay the application fee for expanded practice
certification specified in 16.2.10 NMAC.
D. The doctor of
oriental medicine shall submit, with the application, proof of:
(1) current certification by the board for basic injection
therapy; or
(2) any course combining basic injection therapy and injection
therapy, as they are specified in the board’s rules, or otherwise in accordance
with law, must be completed within two (2) years of the start of the course.
E. The doctor of
oriental medicine shall submit, with the application, proof of successful
completion of the injection therapy educational course approved by the board.
[16.2.19.12 NMAC – Rp,
16.2.19.12 NMAC, 6-16-2015]
16.2.19.13 INTRAVENOUS THERAPY
CERTIFICATION: The board shall issue to a doctor
of oriental medicine, certification for intravenous therapy, upon completion of
the course prerequisites including board certification in basic injection
therapy, and three (3) hours of college level biochemistry, and the following
requirements.
A. The doctor of
oriental medicine shall be a doctor of oriental medicine in good standing.
B. The doctor of
oriental medicine shall submit to the board the completed application form provided
by the board.
C. The doctor of
oriental medicine shall pay the application fee for expanded practice
certification specified in 16.2.10 NMAC.
D. The doctor of
oriental medicine shall submit, with the application, proof of successful
completion of an intravenous therapy educational course approved by the board.
[16.2.19.13 NMAC – Rp,
16.2.19.13 NMAC, 6-16-2015]
16.2.19.14 INTRAVENOUS THERAPY EXPANDED PRACTICE CERTIFICATION: The board shall only issue certification to applicants
after successful completion of the Intravenous Therapy Expanded Practice
Course, and successful
completion and documentation of a practicum to include three hundred (300)
hours under the supervision of a board approved physician and one hundred fifty
(150) individual patients to be completed within two (2) years of completion of
the coursework.
[16.2.19.14 NMAC – N,
6-16-2015]
16.2.19.15 BIOIDENTICAL HORMONE THERAPY
CERTIFICATION: The board shall issue to a doctor of oriental
medicine, certification for bioidentical hormone therapy, upon completion of
the following requirements:
A. the doctor of
oriental medicine shall be a doctor of oriental medicine in good standing;
B. the doctor of
oriental medicine shall submit to the board the completed application form
provided by the board;
C. the doctor of
oriental medicine shall pay the application fee for expanded practice
certification specified in 16.2.10 NMAC; and
D. the doctor of
oriental medicine shall submit, with the application, proof of successful
completion of the bioidentical hormone therapy educational course approved by
the board.
[16.2.19.15 NMAC – Rp,
16.2.19.14 NMAC, 6-16-2015]
16.2.19.16 EXPANDED PRACTICE CERTIFICATION
RENEWAL: If a doctor of oriental medicine certified
for expanded prescriptive authority does not complete all expanded prescriptive
authority continuing education requirements specified in 16.2.9.9 NMAC before
the end of the sixty (60) day grace period, the expanded prescriptive authority
certification is expired and that licensee shall not be certified for expanded
prescriptive authority until the continuing education is completed. Provided that all other renewal requirements
have been received by the board, such a licensee shall continue to be licensed
as a doctor of oriental medicine and is authorized for that scope of practice
but shall not be authorized for the relevant expanded prescriptive authority
scope of practice. For an expired
expanded prescriptive authority certification, if a properly completed
application for certification renewal, including proof of completion of the
required expanded prescriptive authority continuing education, is received at
the board office within one (1) year of the last regular renewal date, the
expanded prescriptive authority certification shall be renewed if all the
requirements of late certification renewal during the sixty (60) day grace
period provided by Section 61-14A-15 NMSA 1978 are completed, in addition to
the requirements of 16.2.8.11 NMAC, and the licensee also pays the fee for
expired certification renewal specified in 16.2.10 NMAC. The licensee must notify the board of the
correct current mailing address and of any address changes within ten (10) days
of the change. A doctor of oriental
medicine who fails to renew an expired license by the next July 31 annual
license renewal date or who fails to complete any required continuing education
specific to his prescriptive authority certification shall be required to reapply
as a new applicant for expanded practice, certification the expired license
number of any doctor of oriental medicine certified in expanded practice who
fails to renew in a timely manner in accordance with board rules. The Board will promptly report to the board of
Pharmacy when the expired license is renewed or reinstated.
[16.2.19.16 NMAC – Rp,
16.2.19.15 NMAC, 6-16-2015]
16.2.19.17 TRANSITION PROVISIONS:
A. A doctor of
oriental medicine, previously certified for extended prescriptive authority
including prolotherapy, (Rx1) as of the effective
date of this section, shall be automatically certified for basic injection
therapy and prolotherapy using previously taught and
appropriate injection routes and only substances listed in Paragraph (1) of
Subsection F of 16.2.20.8 NMAC under the provisions of 16.2.19.10 NMAC.
B. A doctor of
oriental medicine, previously certified for the expanded prescriptive authority
(Rx2) as of the effective date of this section, shall be automatically
certified for:
(1) injection therapy under the provisions of 16.2.19.11 NMAC
basic injection therapy certification is automatically superseded by
injection therapy certification;
(2) intravenous therapy under the provisions of 16.2.19.12 NMAC;
and
(3) bioidentical hormone therapy under the provisions of
16.2.19.13 NMAC.
[16.2.19.17 NMAC – Rp,
16.2.19.16 NMAC, 6-16-2015]
16.2.19.18 LICENSE DESIGNATION:
The designation for expanded practice shall follow the license number on
the license and shall reflect the respective modules of certification: Rx basic
injection, Rx injection, Rx intravenous, Rx hormones.
[16.2.19.18 NMAC – Rp,
16.2.19.17 NMAC, 6-16-2015]
16.2.19.19 ULTRASOUND CREDENTIALING: A licensed doctor of oriental medicine may utilize musculoskeletal
diagnostic ultrasound and ultrasound guidance of procedures with the RMSK
credential from ARDMS, the American registry of diagnostic medical sonography. A licensed doctor of oriental medicine (DOM)
who wishes to practice diagnostic musculoskeletal ultrasound and ultrasound
guidance of procedures shall register with the board of acupuncture and
oriental medicine (BAOM) to be provisionally credentialed to practice
diagnostic musculoskeletal ultrasound and ultrasound guided procedures upon
completion of a minimum of thirty (30) hours in BAOM approved courses. Within thirty
six (36) months of provisional credentialing, the doctor of oriental medicine
shall submit to the BAOM proof of scheduling for RMSK testing with ARDMS. If
the provisional credentialing period is continued to thirty six (36) months
without ARDMS RMSK credentialing, the provisionally credentialed DOM shall
submit proof of thirty (30) hours of continuing education in courses approved
by the BAOM. Provisional credentialing shall lapse within forty eight (48)
months of initial provisional credentialing. Ultrasound credentialing does not
require certification in expanded practice.
[16.2.19.19 NMAC – Rp,
16.2.19.18 NMAC, 6-16-2015]
History of repealed material.
16.2.19 NMAC, Expanded Practice Certifications, filed 10-29-2009, repealed 6-16-2015